Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib long-term extension in ulcerative colitis
2016-000674-38Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of upadacitinib in autoimmune colitis (2 arms), sponsored by AbbVie Inc. Primary endpoints: Incidence of adverse events, Change in vital signs and physical examination results and 2 more. Started Jul 2016; status: active.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-000674-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000674-38.